Navigation Links
Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform
Date:7/22/2014

SOUTH EASTON, Mass., July 22, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") and Parabase Genomics ("Parabase"), (together "the companies"), today announced they have entered into a strategic research and development agreement (the "collaboration"). Under the terms of the collaboration, PBI will develop a front-end, sample preparation method for Parabase's enhanced neonatal molecular diagnostics and newborn confirmatory testing process. The sample preparation method will be based on PBI's patented and enabling Pressure Cycling Technology ("PCT") platform.

Each year around 4 million babies are born in the United States, with approximately 400,000 admitted to the Neonatal Intensive Care Unit ("NICU"). Roughly 150,000 newborns need at least one single-gene test, since many of the approximately 4,000 identified single-gene diseases present in the first month of life. Early diagnosis is critical so that treatment to prevent mortality or lifelong debilitation can be quickly initiated. Unfortunately, it is difficult to diagnose genetic disease in newborns based on symptoms alone as 80% of cases present with nonspecific or similar symptoms that can have upwards of 160 possible different diagnoses. Serially testing single genes in these cases, which is the current state-of-the-art, can take many months and be prohibitively expensive.

Dr. Andy Bhattacharjee, Chief Scientific Officer and Founder of Parabase Genomics, said: "Parabase uses targeted next generation sequencing ("NGS") to offer comprehensive test panels to diagnose single-gene conditions in newborns. Our goal is to improve the standard-of-care in NICUs by replacing hundreds of currently used single-gene-disorder tests with our LifeTime NewbornDx™ sequencing service to simultaneously evaluate 350 genes representing genetic disorders in the newborn period. We plan t
'/>"/>

SOURCE Pressure BioSciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Failure to Take Medicine Linked to Unnecessary Hospital Visits, Especially for Medicare Patients Taking High Blood Pressure or High Cholesterol Medications
3. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
4. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
5. Negative Pressure Wound Therapy (NPWT) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
6. Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities
7. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
8. MinuteClinic Joins with American Heart Association to Help Americans Reduce High Blood Pressure
9. Long-Term Use of Blood Pressure Medications that Promote Sun Sensitivity May Increase Risk of Lip Cancer in Non-Hispanic Whites
10. Social Norms, Life Changes and Increasing Pressures Contribute to Substance Abuse Among Adult Women
11. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 The Assistance Fund ... This program provides financial assistance for copay to individuals ... to announce the addition of the Melanoma Copay Assistance ... Mark McGreevy , executive director. "With each additional program ... of a world where no one is denied access ...
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage ... regeneration, today announced that J.J. Finkelstein , chief ... corporate overview at two upcoming investor conferences. ... th Annual Microcap Conference on Thursday May 28, ... at 11:00 am EDT.  A webcast will be available ...
(Date:5/22/2015)... May 22, 2015  The Mesothelioma Victims Center ... of mesothelioma get the best possible compensation, and they ... with this rare cancer caused by exposure to ... information related to treatment options such as a ... the Mesothelioma Victims Center anytime at 866-714-6466. ...
Breaking Medicine Technology:The Assistance Fund Adds Melanoma Assistance Program 2RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5
... 5, 2007 - Synta,Pharmaceuticals Corp., (NASDAQ: SNTA) ... commercializing small,molecule drugs to treat severe medical ... of overall survival (OS) time,for patients in ... clinical trial in metastatic melanoma for its,lead ...
... 5, 2007 - Gloucester,Pharmaceuticals, Inc., a privately held ... romidepsin as a,treatment for cutaneous T-cell lymphoma (CTCL) ... American Society of,Clinical Oncology (ASCO) Annual Meeting being ... of an interim analysis of a phase II,study ...
Cached Medicine Technology:Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 2Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 3Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 4Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 5Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 6Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 7Gloucester Pharmaceuticals Reports Positive Interim Phase II Data,on Romidepsin for T-Cell Lymphomas at the 2007 American Society of,Clinical Oncology Annual Meeting 2Gloucester Pharmaceuticals Reports Positive Interim Phase II Data,on Romidepsin for T-Cell Lymphomas at the 2007 American Society of,Clinical Oncology Annual Meeting 3
(Date:5/23/2015)... Add High-Quality prismatic refractions into footage using ProFlare ... simple as dragging and dropping footage into the FCPX timeline ... , Including over 80 stunning flares, ProFlare 5K Prism ... the ultimate bundle for adding prismatic refractions to any video. ... movie files designed for Final Cut Pro X, but are ...
(Date:5/22/2015)... Pioneer Millworks, the largest reclaimed wood ... designing with reclaimed wood, introducing their latest reclaimed wood ... Their newest offerings, Vat 35, Reclaimed Teak , ... to America's largest design event. , “Designers, architects, builders, ... anxious to see and feel the variety of wood ...
(Date:5/22/2015)... Liverpool, OH (PRWEB) May 22, 2015 ... announced that Kyle Johnson, the health system’s Chief Financial ... other interests. Johnson has served as the company CFO ... Wesley West will be joining the health system as ... on an interim basis, while the Board of Trustees ...
(Date:5/22/2015)... May 22, 2015 Omar Ahmad Barrada, ... to participate in the 2015 Congress of Future Medical ... as a gathering of “America’s highest achieving high school ... of healthcare, set new goals and learn better study ... live surgery, during which we can ask the surgeons ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 “It’s ... MS/CCC, SLP, RAC-CT, CHHRP-QT, Vice President of Clinical ... very important ‘language’ that impacts how care is ... leader in long term care reimbursement, operations and ... programs and talent management, launches a new series ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3
... for its treatment by the FDA, following a clinical ... Taxotere survived an average of 11.4 months without disease ... ,The drug will be used before radiation, ... advanced squamous cell head and neck cancer. Its side ...
... human gene therapy for Parkinson's disease has given the green ... reducing symptoms for patients,// according to the reports of two ... yesterday and last week the researchers reported that each of ... trials received some benefit and none had significant side effects. ...
... A new experimental vaccine developed by scientists in the US ... help prevent the disease that has kills one million// people ... S and developed by Walter Reed Army Institute of Research ... percent for up to 18 months after vaccination among children ...
... a computer-driven system can significantly reduce the duration ... the intensive// care unit (ICU), as compared with ... ,The study, which was conducted in five medical-surgical ... appears in the second issue for October 2006 ...
... in the October issue of the Journal of the American ... elderly women who have not received// up to the mark ... compared to the younger lot. , ,David Litvak ... colleagues studied the records of 354 breast cancer patients who ...
... turning out to be a big challenge for law enforcement officials ... from the last decade, lock-ups /arrests due to possession of ice ... ,Yet, despite this entire hullabaloo, scientists have not been able ... that is still unclear about the link between this drug and ...
Cached Medicine News:Health News:Gene therapy Beneficial in Parkinson's Disease 2Health News:Gene therapy Beneficial in Parkinson's Disease 3Health News:Computer-Driven System Reduces Patient Mechanical Ventilation Time Significantly 2
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
... complete line of flowmeters, available in ... . They are all available in ... suit your application. With color coded ... gas in use, the Amvex Flowmeter ...
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
... Amvex offers a complete line of ... and CO 2 . They are ... calibrations to best suit your application. ... specific to the gas in use, ...
Medicine Products: